Form 4: Lyell Immunopharma Executive Sells Shares

Lyell Immunopharma's Chief Medical Officer, David Shook, reported a transaction involving the sale of 1,977 shares of common stock.

Summary

• David Shook, Chief Medical Officer of Lyell Immunopharma, Inc., reported a transaction on June 10, 2026.
• The transaction involved the sale of 1,977 shares of common stock at a price of $12.64 per share.
• This sale was to cover tax withholding obligations from the settlement of vested restricted stock units.
• Following this transaction, Mr. Shook beneficially owns 20,923 shares of common stock.
• The filing also notes that Mr. Shook acquired 1,000 shares on May 18, 2026, under the Issuer's 2021 Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard insider transaction for tax purposes rather than a strategic decision about the company's future.

Positives

• The sale of shares was to cover tax withholding obligations, indicating a standard procedure for equity compensation.
• Mr. Shook continues to beneficially own a significant number of shares (20,923) after the transaction.
• Acquisition of 1,000 shares under the Employee Stock Purchase Plan suggests ongoing participation in company stock ownership.

Negatives

• A portion of the executive's holdings was sold, reducing their direct ownership.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for executives and directors regarding their stock transactions. These filings provide transparency into insider activity but do not typically offer strategic insights into the company's performance or future prospects.

Stakeholder Impact

• Shareholders: Increased transparency into executive stock transactions. The sale is for tax withholding, which is a common and expected event.
• Employees: The acquisition of shares under the ESPP indicates continued employee engagement and investment in the company.
• Management: Standard reporting of compensation-related stock transactions.

Key Dates

Keywords

Lyell Immunopharma, Form 4, Insider Trading, Stock Sale, Executive Compensation, Restricted Stock Units, Tax Withholding, Beneficial Ownership